Condition
ARDS Due to Disease Caused by SARS Co-V-2
Total Trials
4
Recruiting
0
Active
0
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 3 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
Trial Status
Completed3
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT06456606CompletedPrimary
Cardiopulmonary Effects of Prone Position in CARDS
NCT05910996CompletedPrimary
Prediction of Conversion From Vv-ECMO to Va-ECMO in COVID-19 Patients
NCT06218862CompletedPrimary
Clinical Effects of Sivelestat Sodium on Improving ARDS in Patients With COVID-19
NCT05721768UnknownPrimary
Altered Respiratory Compliance Under Invasive Mechanical Ventilation in SARS-CoV-2 & Development of Respiratory Sequels
Showing all 4 trials